Cardiac transplantation: the final therapeutic option for the treatment of heart failure
- PMID: 10952425
- DOI: 10.1097/00001573-200005000-00010
Cardiac transplantation: the final therapeutic option for the treatment of heart failure
Abstract
End-stage heart failure is still associated with a decrease in quality and prognosis of life. Cardiac transplantation remains the final extraordinary therapeutic option for the treatment of truly irreversible end-stage heart failure in all age groups. The selection process of candidates and the acceptance of patients with relative contra-indications is characterized by the experience and skills of an interdisciplinary transplant team, which should have access to different mechanical circulatory support systems for short-term or long-term use: bridging to transplant as well as for recovery.
Similar articles
-
Heart transplantation an answer for end-stage heart failure.Crit Care Nurs Clin North Am. 2003 Dec;15(4):489-94. doi: 10.1016/s0899-5885(02)00087-4. Crit Care Nurs Clin North Am. 2003. PMID: 14717394 Review.
-
Intervention: LVADs--from an imaginative leap to clinical decision making.Nat Rev Cardiol. 2010 May;7(5):246-8. doi: 10.1038/nrcardio.2010.36. Nat Rev Cardiol. 2010. PMID: 20418903 No abstract available.
-
Current status of cardiac transplantation and mechanical circulatory support.Curr Heart Fail Rep. 2009 Mar;6(1):28-33. doi: 10.1007/s11897-009-0006-8. Curr Heart Fail Rep. 2009. PMID: 19265590 Review.
-
Left ventricular assist devices as bridge to heart transplantation: The Niguarda Experience.J Card Surg. 2003 Mar-Apr;18(2):107-13. doi: 10.1046/j.1540-8191.2003.02012.x. J Card Surg. 2003. PMID: 12757336
-
The Interdisciplinary Heart Failure and Transplant Program Münster: a 5-year experience.Int J Cardiol. 1995 Jun 2;50(1):7-17. doi: 10.1016/0167-5273(95)02344-v. Int J Cardiol. 1995. PMID: 7558467
Cited by
-
Effect of everolimus on the immunomodulation of the human neutrophil inflammatory response and activation.Cell Mol Immunol. 2015 Jan;12(1):40-52. doi: 10.1038/cmi.2014.24. Epub 2014 Jun 2. Cell Mol Immunol. 2015. PMID: 24882386 Free PMC article.
-
Sphingosine 1-Phosphate Receptor Modulator Fingolimod (FTY720) Attenuates Myocardial Fibrosis in Post-heterotopic Heart Transplantation.Front Pharmacol. 2017 Sep 15;8:645. doi: 10.3389/fphar.2017.00645. eCollection 2017. Front Pharmacol. 2017. PMID: 28966593 Free PMC article.
-
Neutrophil mediated smooth muscle cell loss precedes allograft vasculopathy.J Cardiothorac Surg. 2010 Jun 22;5:52. doi: 10.1186/1749-8090-5-52. J Cardiothorac Surg. 2010. PMID: 20569484 Free PMC article.
-
Role of Mitogen-Activated Protein Kinases in Myocardial Ischemia-Reperfusion Injury during Heart Transplantation.J Transplant. 2012;2012:928954. doi: 10.1155/2012/928954. Epub 2012 Mar 18. J Transplant. 2012. PMID: 22530110 Free PMC article.
-
Isolation and characterization of a Sca-1+/CD31- progenitor cell lineage derived from mouse heart tissue.BMC Biotechnol. 2014 Aug 9;14:75. doi: 10.1186/1472-6750-14-75. BMC Biotechnol. 2014. PMID: 25106452 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical